The Company is applying its insights in the structure, biology and function of individual PI3K and HDAC isoforms to design and develop innovative new medicines with significant clinical and commercial potential.
Karus is an Oxford, UK-based, privately-held company with a strong investor base, including SV Life Sciences, New Leaf Ventures, Novo A/S and IP Group.
The company is led by a highly-experienced management team with a track-record of creating, developing and partnering therapeutic programs in Europe and North America.
Chief Executive Officer
“Karus is dedicated to developing innovative therapeutics that can unlock the power of the human immune system to treat cancer. Our goal is to transform the treatment of diseases with a high unmet medical need through our proprietary, isoform-selective PI3K and HDAC inhibitors.”